Gvoke® Kit is now available for the treatment of severe hypoglycemia in adult and pediatric patients with diabetes 2 years of age and older.
Gvoke is a ready-to-use, room-temperature stable liquid glucagon. The new kit contains 1 single-dose sterile syringe with markings for 0.1mL (0.5mg pediatric dose) and 0.2mL (1mg adult dose), and 1 single-dose vial containing 0.2mL of Gvoke.
The antihypoglycemic agent is also available as a prefilled syringe (Gvoke PFS) and autoinjector (Gvoke HypoPen). Treatment is administered subcutaneously into the lower abdomen, outer thigh, or outer upper arm.
“We are pleased to offer another ready-to-use rescue form of Gvoke for the millions of people with diabetes at increased risk of a severe low blood sugar event,” said Kevin McCulloch, Xeris’ Chief Commercial Officer. “Gvoke Kit contains the same room-temperature liquid-stable glucagon as in Gvoke HypoPen® and Gvoke® PFS but may be preferred by those who would rather draw up the appropriate rescue dose using a vial and syringe.”
Xeris Biopharma announces Gvoke® Kit is now available for the treatment of severe hypoglycemia in adults and children with diabetes ages 2 and above. News release. Xeris Biopharma Holdings, Inc. Accessed March 16, 2022. https://www.businesswire.com/news/home/20220316005150/en/Xeris-Biopharma-Announces-Gvoke%C2%AE-Kit-Is-Now-Available-for-the-Treatment-of-Severe-Hypoglycemia-in-Adults-and-Children-With-Diabetes-Ages-2-And-Above